Research

Technology and empathy help make remote working a success for Elsevier

We at Elsevier were pleased to be one of five companies recognized for their ability to keep remote workers rooted in company culture in this recent Comparably article. Like many organizations during the pandemic, we had to quickly adapt to remote working on a large scale for our international workforce. As the article notes, “Elsevier …

Technology and empathy help make remote working a success for Elsevier Read More »

AstraZeneca and Regeneron Collaborate to Research, Develop and Commercialize Therapies for Obesity

Shots: The companies collaborated to research, develop & commercialize small molecules directed against the GPR75 target with the potential to treat obesity and related co-morbidities The collaboration builds on the findings from the Regeneron Genetics Center of rare genetic mutations in the GPR75 gene associated with protection against obesity and on early joint research initiated …

AstraZeneca and Regeneron Collaborate to Research, Develop and Commercialize Therapies for Obesity Read More »

Johnson & Johnson podría ser menos eficaz contra la variante delta

Muchos de los que recibieron la vacuna pueden necesitar refuerzos, dijeron los autores. Pero las autoridades sanitarias federales no recomiendan segundas dosis.

Johnson & Johnson podría ser menos eficaz contra la variante delta

Muchos de los que recibieron la vacuna pueden necesitar refuerzos, dijeron los autores. Pero las autoridades sanitarias federales no recomiendan segundas dosis.

How Aduhelm, an Unproven Alzheimer’s Drug, Got Approved

Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab.

How an Unproven Alzheimer’s Drug Got Approved

Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab.

Antibody Purification: A Deeper Look into Service Providers Landscape

Over time, several innovative technologies have been developed to support the designing and manufacturing of various types of antibody products; however, the aforementioned processes are characterized by high costs and technical complexities, especially during the production and downstream processing steps. Therefore, it is challenging for new entrants and companies with limited resources and capital, to …

Antibody Purification: A Deeper Look into Service Providers Landscape Read More »

Cancer doc: To boost minority participation, we have fliers in our clinic saying “Ask me about a clinical trial”

Minority groups get left out of clinical trials and studies for many reasons, including lack of access, awareness and trust in the healthcare system. But, according to panelists at MedCity INVEST Precision Medicine, researchers along with patient advocates can help tackle these hurdles by working together and being intentional in their approach.

Immunocytokines – The Power of Fusion Proteins

Cancer is one of the leading causes of death worldwide, accounting for an estimated 0.6 million deaths in 2020, in the US alone. The World Health Organization has estimated the number of new cancer cases to rise by 70%, worldwide, over the next 20 years. It is a well-known fact that the conventional treatment options, …

Immunocytokines – The Power of Fusion Proteins Read More »

Report calls for better work culture in UK research

Create a positive working culture for the UK’s researchers, or watch the country’s standing as an innovation leader crumble, says new report. From the Oxford vaccine to the RECOVERY trial, all eyes have been on the triumph of British science in recent months. But future success is at risk if we do not create a …

Report calls for better work culture in UK research Read More »

PlantForm Signs Research and Development Agreement with Bio-Manguinhos/Fiocruz to Develop Biosimilar Pembrolizumab

Shots: The agreement facilitates PlantForm’s collaborations in Brazil to provide affordable, effective cancer drugs to millions of Brazilians The 3yrs. research and development collaboration will culminate in protocols for P-I and P-III clinical trials. The companies will take biosimilar pembrolizumab to world markets, following the completion of clinical trials in Brazil Pembrolizumab is a biosimilar …

PlantForm Signs Research and Development Agreement with Bio-Manguinhos/Fiocruz to Develop Biosimilar Pembrolizumab Read More »

Science Plays the Long Game. But People Have Mental Health Issues Now.

I’ve reported on behavior and mental health for 20 years. As I exit, I can’t help but wonder why researchers have placed so little emphasis on helping people in distress today.

Science Plays the Long Game. But People Have Mental Health Issues Now.

I’ve reported on behavior and mental health for 20 years. As I exit, I can’t help but wonder why researchers have placed so little emphasis on helping people in distress today.

Science Plays the Long Game. But People Have Mental Health Issues Now.

I’ve reported on behavior and mental health for 20 years. As I exit, I can’t help but wonder why researchers have placed so little emphasis on helping people in distress today.

Cleveland Clinic, IBM launch 10-year tech-enabled research partnership

The healthcare provider and technology giant have entered into a 10-year partnership that will leverage AI, cloud and quantum computing capabilities to accelerate research. The collaboration will include the first private-sector installation of the IBM Quantum System One.

PCR Buffer: Polymerase Chain Reaction Mediator

PCR buffer is a vital component of the Polymerase Chain Reaction, also called molecular photocopying. The reaction has helped scientists worldwide study DNA by providing its ample amount from minimal samples. It is almost impossible to carry on a PCR reaction without a buffer. But what is the main function of a PCR Buffer? How …

PCR Buffer: Polymerase Chain Reaction Mediator Read More »

La búsqueda de tratamientos contra la COVID-19 quedó rezagada

El desarrollo de las vacunas superó las expectativas de todos. Pero durante los próximos meses muchas personas enfermarán y, lamentablemente, los médicos tienen pocos fármacos para tratarlas.

La búsqueda de tratamientos contra la COVID-19 quedó rezagada

El desarrollo de las vacunas superó las expectativas de todos. Pero durante los próximos meses muchas personas enfermarán y, lamentablemente, los médicos tienen pocos fármacos para tratarlas.

How the Search for Covid-19 Treatments Faltered While Vaccines Sped Ahead

Vaccine development exceeded everyone’s expectations. But the next few months will still bring many sick people — and doctors have woefully few drugs with which to treat them.

Single-Cell Sequencing: The New Era of Gene Expression Analysis

For developing an improved understanding of the interactions of individual cells within their microenvironment, advanced molecular probing solutions are being used by researchers across the globe. In this context, high-throughput single-cell analysis, has emerged as a powerful analytical technique for studying individual cells, enabling researchers to study gene expression at single cell resolution. Single-cell sequencing …

Single-Cell Sequencing: The New Era of Gene Expression Analysis Read More »

An introduction to the new NIHR National Patient Recruitment Centres

A new network of patient recruitment centres is set to shape the future of commercial clinical trials in the UK by offering new approaches to conduct late-phase, large-scale research projects. In a recent pharmaphorum webinar leaders from the NIHR’s five National Patient Recruitment Centres (NPRCs) outlined how they could bring cutting-edge therapies to greater numbers …

An introduction to the new NIHR National Patient Recruitment Centres Read More »

Egle Identifies First Novel Regulatory T-cell Targets Under its Collaboration with Takeda

Shots: Egle has achieved the first milestone in its research agreement with Takeda, signed in June’2020. Egle will validate novel tumor-infiltrating regulatory T-cell targets while Takeda will develop the potential therapies Egle has leveraged its unique bioinformatic & translational capabilities to identify targets Following the achievement of the target identification, Egle will receive an R&D …

Egle Identifies First Novel Regulatory T-cell Targets Under its Collaboration with Takeda Read More »

Eli Lilly Signs an Exclusive Agreement with Precision BioSciences on Genome Editing Research

Shots: Precision to receive $100M upfront, $35M as an equity investment and will receive $420M as milestones/ product along with royalties on sales of licensed products emerges from the collaboration Precision will lead to pre-clinical research and IND-enabling activities while Lilly will lead clinical development and commercialization and have the right to select up to …

Eli Lilly Signs an Exclusive Agreement with Precision BioSciences on Genome Editing Research Read More »

Havas Health & You launches Behind the Mask

Behind the Mask is a global research initiative to document health experiences during the COVID-19 pandemic and beyond. Havas Health & You (HH&Y) has launched the details of a long-term global research project, Behind the Mask, a longitudinal, multi-armed study that focuses on documenting the ongoing evolution of health and wellness. This sector has seen …

Havas Health & You launches Behind the Mask Read More »

Qiagen Collaborate with TScan to Develop T Cell-Based COVID-19 Test

Shots: TScan signs exclusive research and option to license agreement with Qiagen to develop T cell-based laboratory tests for detecting prior exposure to the SARS-CoV-2 Qiagen gets an option to license the rights and IP for several of TScan discovered immunodominant T cell targets, associated sequences and relevant data for the development and commercialization of …

Qiagen Collaborate with TScan to Develop T Cell-Based COVID-19 Test Read More »

Insights+ KOL Articles: The New Normal and Covid-19 Vaccine Development

Since the virus outbreak in China, all eyes are on the most awaited Covid-19 vaccine offering a glimmer of hope. Abide by social distancing, wearing a mask, and frequent hand washing – until we have a vaccine. This new mantra amidst all misery has created hope in the hearts of many. We have to accept …

Insights+ KOL Articles: The New Normal and Covid-19 Vaccine Development Read More »

Fill / Finish Services Industry: Impact of the Swelling Biopharmaceutical Pipelines

Biopharmaceuticals represent the most rapidly growing and high-value segment of the pharmaceutical industry. Growing at an annualized rate of ~12%, the industry stands tall with more than 5,000 biologics in development and over 300 FDA approved biologics, since 2002. Biologic drug development is characterized by high quality standards and a rapidly growing demand for novel …

Fill / Finish Services Industry: Impact of the Swelling Biopharmaceutical Pipelines Read More »

In Vitro ADME Testing Services: Emerging Opportunities for Service Providers

According to the US Food and Drug Administration (USFDA), less than 10% of investigational new drug (IND) candidates progress beyond the submission of a new drug application (NDA); this implies that majority of the drug / therapy candidates fail to reach the market owing to unacceptable safety and efficacy profiles and the problems associated with …

In Vitro ADME Testing Services: Emerging Opportunities for Service Providers Read More »

Peptide APIs – A Deeper Look Into Contract Manufacturing Market

The recent years have portrayed the renaissance of peptide APIs, as pharma industry has once again turned its attention towards the potential of therapeutic peptides. Adoption of peptides as therapeutic agents have side-lined some of the earlier concerns associated with them, such as bioavailability, and has led to manufacturing of high-quality peptides in a larger …

Peptide APIs – A Deeper Look Into Contract Manufacturing Market Read More »

Increasing Rate of Drug Failure has Prompted the Drug Developers to Rely on CROs offering In Vitro ADME Testing Services for their Outsourcing Requirements

It is important to note that the process of drug discovery is extremely demanding, both in terms of capital and time. In fact, the overall amount spent on R&D initiatives in the pharmaceutical / biotechnology sector has increased from around USD 128 billion in 2008 to USD 165 billion in 2018. Moreover, only a small …

Increasing Rate of Drug Failure has Prompted the Drug Developers to Rely on CROs offering In Vitro ADME Testing Services for their Outsourcing Requirements Read More »

Targeted Protein Degradation is Anticipated to Become a Major Therapeutic Modality in the Coming Decade

The targeted protein degradation approach is believed to possess the potential to unlock the undruggable proteome, which was traditionally considered to be inaccessible. Compared to conventional inhibition strategies, degradation offers several benefits, which include the opportunity to completely remove aberrant proteins and associated systemic malfunctions. As a result, targeted protein degradation-based therapeutics have generated enthusiasm …

Targeted Protein Degradation is Anticipated to Become a Major Therapeutic Modality in the Coming Decade Read More »

In Silico / Computer-Aided Drug Discovery Service Providers for Large Molecules

Over time, the complexities associated with drug discovery have increased, especially in case of large molecule drugs, which are inherently more complex than conventional small molecules. As a result, an increase in the overall research and development (R&D) expenditure in the pharmaceutical / biotechnology sector has been witnessed. In addition to the complexities involved, the …

In Silico / Computer-Aided Drug Discovery Service Providers for Large Molecules Read More »